Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

277 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Lung Cancer Screening in Persons Who Never Smoked Has to be Evaluated-A Response to Letter to the Editor.
Kerpel-Fronius A, Tammemägi MC, Cavic M, Huber RM; Diagnostics Working Group; Yang D, Zulueta J, Viola L, Mohan A, Lee CT, Cavic M, Schmidt H, Kazerooni E, Sales Dos Santos R, Kerpel-Fronius A, Henschke C, Ventura L, Jiang L, Sozzi G, Tammemägi M, Lam S, Huber R; ED & Screening Committee. Kerpel-Fronius A, et al. Among authors: huber rm. J Thorac Oncol. 2022 Feb;17(2):e20-e21. doi: 10.1016/j.jtho.2021.12.009. J Thorac Oncol. 2022. PMID: 35074232 Free article. No abstract available.
Screening for Lung Cancer in Individuals Who Never Smoked: An International Association for the Study of Lung Cancer Early Detection and Screening Committee Report.
Kerpel-Fronius A, Tammemägi M, Cavic M, Henschke C, Jiang L, Kazerooni E, Lee CT, Ventura L, Yang D, Lam S, Huber RM; members of the Diagnostics Working Group; ED and Screening Committee. Kerpel-Fronius A, et al. Among authors: huber rm. J Thorac Oncol. 2022 Jan;17(1):56-66. doi: 10.1016/j.jtho.2021.07.031. Epub 2021 Aug 27. J Thorac Oncol. 2022. PMID: 34455065 Free article.
Lung Cancer Screening Considerations During Respiratory Infection Outbreaks, Epidemics or Pandemics: An International Association for the Study of Lung Cancer Early Detection and Screening Committee Report.
Huber RM, Cavic M, Kerpel-Fronius A, Viola L, Field J, Jiang L, Kazerooni EA, Koegelenberg CFN, Mohan A, Sales Dos Santos R, Ventura L, Wynes M, Yang D, Zulueta J, Lee CT, Tammemägi MC, Henschke CI, Lam S; members of the Diagnostics Working Group; Early Detection and Screening Committee. Huber RM, et al. J Thorac Oncol. 2022 Feb;17(2):228-238. doi: 10.1016/j.jtho.2021.11.008. Epub 2021 Dec 3. J Thorac Oncol. 2022. PMID: 34864164 Free PMC article.
International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma.
Travis WD, Brambilla E, Noguchi M, Nicholson AG, Geisinger KR, Yatabe Y, Beer DG, Powell CA, Riely GJ, Van Schil PE, Garg K, Austin JH, Asamura H, Rusch VW, Hirsch FR, Scagliotti G, Mitsudomi T, Huber RM, Ishikawa Y, Jett J, Sanchez-Cespedes M, Sculier JP, Takahashi T, Tsuboi M, Vansteenkiste J, Wistuba I, Yang PC, Aberle D, Brambilla C, Flieder D, Franklin W, Gazdar A, Gould M, Hasleton P, Henderson D, Johnson B, Johnson D, Kerr K, Kuriyama K, Lee JS, Miller VA, Petersen I, Roggli V, Rosell R, Saijo N, Thunnissen E, Tsao M, Yankelewitz D. Travis WD, et al. Among authors: huber rm. J Thorac Oncol. 2011 Feb;6(2):244-85. doi: 10.1097/JTO.0b013e318206a221. J Thorac Oncol. 2011. PMID: 21252716 Free PMC article. Review.
Interleukin-22 is frequently expressed in small- and large-cell lung cancer and promotes growth in chemotherapy-resistant cancer cells.
Kobold S, Völk S, Clauditz T, Küpper NJ, Minner S, Tufman A, Düwell P, Lindner M, Koch I, Heidegger S, Rothenfuer S, Schnurr M, Huber RM, Wilczak W, Endres S. Kobold S, et al. Among authors: huber rm. J Thorac Oncol. 2013 Aug;8(8):1032-42. doi: 10.1097/JTO.0b013e31829923c8. J Thorac Oncol. 2013. PMID: 23774470 Free article.
The Potential of Combined Immunotherapy and Antiangiogenesis for the Synergistic Treatment of Advanced NSCLC.
Manegold C, Dingemans AC, Gray JE, Nakagawa K, Nicolson M, Peters S, Reck M, Wu YL, Brustugun OT, Crinò L, Felip E, Fennell D, Garrido P, Huber RM, Marabelle A, Moniuszko M, Mornex F, Novello S, Papotti M, Pérol M, Smit EF, Syrigos K, van Meerbeeck JP, van Zandwijk N, Yang JC, Zhou C, Vokes E. Manegold C, et al. Among authors: huber rm. J Thorac Oncol. 2017 Feb;12(2):194-207. doi: 10.1016/j.jtho.2016.10.003. Epub 2016 Oct 8. J Thorac Oncol. 2017. PMID: 27729297 Free article. Review.
Brigatinib in Crizotinib-Refractory ALK+ NSCLC: 2-Year Follow-up on Systemic and Intracranial Outcomes in the Phase 2 ALTA Trial.
Huber RM, Hansen KH, Paz-Ares Rodríguez L, West HL, Reckamp KL, Leighl NB, Tiseo M, Smit EF, Kim DW, Gettinger SN, Hochmair MJ, Kim SW, Langer CJ, Ahn MJ, Kim ES, Kerstein D, Groen HJM, Camidge DR. Huber RM, et al. J Thorac Oncol. 2020 Mar;15(3):404-415. doi: 10.1016/j.jtho.2019.11.004. Epub 2019 Nov 19. J Thorac Oncol. 2020. PMID: 31756496 Free article. Clinical Trial.
277 results